An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV‐2

An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV‐2

Abstract Monoclonal antibodies targeting the SARS‐CoV‐2 spike (S) neutralize infection and are efficacious for the treatment of COVID‐19. However, SARS‐CoV‐2 variants, notably sublineages of B.1.1.529/omicron, have emerged that escape antibodies in clinical use. As an alternative, soluble decoy rece...

Full description

Bibliographic Details
Main Authors: Lianghui Zhang, Krishna K Narayanan, Laura Cooper, Kui K Chan, Savanna S Skeeters, Christine A Devlin, Aaron Aguhob, Kristie Shirley, Lijun Rong, Jalees Rehman, Asrar B Malik, Erik Procko
Format: Article
Language:English
Published: Springer Nature 2022-11-01
Series:EMBO Molecular Medicine
Subjects:
angiotensin‐converting enzyme 2
COVID‐19
decoy
omicron
receptor
SARS‐CoV‐2
Online Access:https://doi.org/10.15252/emmm.202216109

Internet

https://doi.org/10.15252/emmm.202216109

Similar Items